BREAKING: Novo Nordisk and Eli Lilly Studies Show GLP-1 Drugs Reduce Biological Age by 2 to 3 Years

Novo Nordisk ($NVO) and Eli Lilly ($LLY) have both found that GLP-1 receptor agonists can reverse the biological aging clock by two to three years, according to reporting from MIT Technology Review.
The findings highlight expanding therapeutic possibilities for popular metabolic medications beyond diabetes and weight management, drawing immediate market attention to major pharmaceutical developers as well as telehealth providers like Hims & Hers Health ($HIMS).